MedTrace Logo

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

NCT02477527 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-07-28

Study results available
· View outcomes & findings →

Summary

Switch patients from Atripla to Stribild will be evaluated to see if patients have less sleep disturbances.

Conditions

  • HIV
  • AIDS
  • Sleep Disorders

Interventions

DRUG

Stribild

Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Midtown Medical Center, Tampa, FL

    lead OTHER

Principal Investigators

  • Edward W Braun, MD · Midtown Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-12-31
Completion
2016-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02477527 on ClinicalTrials.gov